{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:41:57Z","timestamp":1788950517597,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"DOI":"10.1186\/s13023-026-04351-0","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T02:45:10Z","timestamp":1777257910000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medical device development and innovation for rare and pediatric populations: a global landscape overview"],"prefix":"10.1186","volume":"21","author":[{"given":"Marc","family":"Dooms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Melvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasum","family":"Peiris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Pohlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durhane","family":"Wong-Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5883-7610","authenticated-orcid":false,"given":"Anneliene Hechtelt","family":"Jonker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of the IRDiRC WG Medical Technologies for Rare Diseases","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"4351_CR1","unstructured":"European Commission. Regulation No 141\/2000 of the European Parliament and of the Council on orphan medical products. 2000."},{"issue":"6","key":"4351_CR2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","volume":"18","author":"T Richter","year":"2015","unstructured":"Richter T, Nestler-Parr S, Babela R, Khan ZM, Tesoro T, Molsen E, et al. Rare disease terminology and definitions\u2014a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18(6):906\u201314. https:\/\/doi.org\/10.1016\/j.jval.2015.05.008.","journal-title":"Value Health"},{"key":"4351_CR3","unstructured":"Rare Diseases International. Operational description of rare diseases. Rare diseases international. https:\/\/www.rarediseasesinternational.org\/fr\/definition-operationnelle-des-maladies-rares\/(2023)."},{"issue":"10464","key":"4351_CR4","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0140-6736(24)02414-0","volume":"404","author":"T Lancet","year":"2024","unstructured":"Lancet T. Hope for rare diseases. Lancet. 2024;404(10464):1701. https:\/\/doi.org\/10.1016\/S0140-6736(24)02414-0.","journal-title":"Lancet"},{"issue":"1","key":"4351_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/cts.12501","volume":"11","author":"HJS Dawkins","year":"2018","unstructured":"Dawkins HJS, Draghia-Akli R, Lasko P, Lau LPL, Jonker AH, Cutillo CM, et al. Progress in rare diseases research 2010\u20132016: an IRDiRC perspective. Clin Transl Sci. 2018;11(1):11\u201320. https:\/\/doi.org\/10.1111\/cts.12501.","journal-title":"Clin Transl Sci"},{"key":"4351_CR6","unstructured":"Access and unmet needs of orphan drugs in 194 countries and 6 areas: a global policy review with content analysis - value in health. https:\/\/www.valueinhealthjournal.com\/article\/S1098-3015(20)34413-2\/fulltext#articleInformation."},{"key":"4351_CR7","unstructured":"Health CFD, R. How to determine if your product is a medical device. FDA. 2023. https:\/\/www.fda.gov\/medical-devices\/classify-your-medical-device\/how-determine-if-your-product-medical-device."},{"key":"4351_CR8","unstructured":"M. MDR - article 2 - definitions. Medical device regulation. https:\/\/www.medical-device-regulation.eu\/2019\/07\/10\/mdr-article-2-definitions\/(2019)."},{"key":"4351_CR9","unstructured":"Health CFD, R. Artificial intelligence and machine learning (AI\/ML)-enabled medical devices. FDA. 2024. https:\/\/www.fda.gov\/medical-devices\/software-medical-device-samd\/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices."},{"key":"4351_CR10","unstructured":"Working group on medtech for rare diseases - IRDiRC. https:\/\/irdirc.org\/working-group-on-medtech-for-rare-diseases\/."},{"key":"4351_CR11","unstructured":"Health CFD, R. Listing of CDRH humanitarian device exemptions. FDA. 2024. https:\/\/www.fda.gov\/medical-devices\/hde-approvals\/listing-cdrh-humanitarian-device-exemptions."},{"key":"4351_CR12","doi-asserted-by":"publisher","unstructured":"Boycott KM, Lau LP, Cutillo CM, Austin CP. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol Med. 2019;11(5):e10486. https:\/\/doi.org\/10.15252\/emmm.201910486.","DOI":"10.15252\/emmm.201910486"},{"issue":"2","key":"4351_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00246-022-03029-1","volume":"44","author":"M T","year":"2023","unstructured":"T M, D K, M G, Ag F. Orphan medical devices and pediatric cardiology \u2013 what interventionists in Europe need to know, and what needs to be done. Pediatr Cardiol. 2023;44(2):271\u201379. https:\/\/doi.org\/10.1007\/s00246-022-03029-1.","journal-title":"Pediatr Cardiol"},{"key":"4351_CR14","unstructured":"FDA, NCATS. Unmet medical device needs for patients with rare diseases. (2016)."},{"issue":"3","key":"4351_CR15","doi-asserted-by":"publisher","first-page":"0347011","DOI":"10.1115\/1.4040489","volume":"12","author":"V Peiris","year":"2018","unstructured":"Peiris V, Xu K, Agler HL, Chen EA, Gopal-Srivastava R, Lappin BM, et al. Children and adults with rare diseases need innovative medical devices. J Med Device. 2018;12(3):0347011\u201318. https:\/\/doi.org\/10.1115\/1.4040489.","journal-title":"J Med Device"},{"key":"4351_CR16","unstructured":"Health CFD, R. Humanitarian device exemption. FDA. 2023. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/humanitarian-device-exemption."},{"issue":"10","key":"4351_CR17","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1080\/17434440.2024.2404257","volume":"21","author":"T Melvin","year":"2024","unstructured":"Melvin T, Dooms MM, Koletzko B, Turner MA, Kenny D, Fraser AG, et al. Orphan and paediatric medical devices in Europe: recommendations to support their availability for on-label and off-label clinical indications. Expert Rev Med Devices. 2024;21(10):893\u2013901. https:\/\/doi.org\/10.1080\/17434440.2024.2404257.","journal-title":"Expert Rev Med Devices"},{"key":"4351_CR18","unstructured":"FDA. Responding to unsolicited requests for off-label information about prescription drugs and medical devices. 2011."},{"issue":"1","key":"4351_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13023-016-0507-y","volume":"11","author":"M Dooms","year":"2016","unstructured":"Dooms M, Cassiman D, Simoens S. Off-label use of orphan medicinal products: a Belgian qualitative study. Orphanet J Rare Dis. 2016;11(1):144. https:\/\/doi.org\/10.1186\/s13023-016-0507-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"4351_CR20","doi-asserted-by":"publisher","first-page":"238","DOI":"10.5582\/irdr.2021.01104","volume":"10","author":"A Fung","year":"2021","unstructured":"Fung A, Yue X, Wigle PR, Guo JJ. Off-label medication use in rare pediatric diseases in the United States. IRDR. 2021;10(4):238\u201345. https:\/\/doi.org\/10.5582\/irdr.2021.01104.","journal-title":"IRDR"},{"key":"4351_CR21","unstructured":"Research CFDEA. Reviews of pediatric studies conducted under BPCA and pediatric assessments conducted under PREA from 2012 - present. FDA. 2025. https:\/\/www.fda.gov\/drugs\/development-resources\/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012."},{"key":"4351_CR22","unstructured":"Commissioner OOT. Humanitarian use device (HUD) designation program. FDA. 2023. https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/humanitarian-use-device-hud-designation-program."},{"key":"4351_CR23","unstructured":"PMDA. Act on Securing quality, efficacy and safety of products including pharmaceuticals and medical device. 1960."},{"key":"4351_CR24","unstructured":"European Union. REGULATION (EU) 2017\/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 on medical devices, Amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and Repealing Council Directives 90\/385\/EEC and 93\/42\/EEC. 2017."},{"key":"4351_CR25","unstructured":"Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98\/79\/EC and Commission decision 2010\/227\/EU. (Text EEA Relevance)Text EEA Relevance. 2017."},{"key":"4351_CR26","unstructured":"MDCG. Clinical evaluation of orphan medical devices. Medical Devices; 2024-10."},{"key":"4351_CR27","unstructured":"European Commission. Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. 2025."},{"key":"4351_CR28","unstructured":"Health CFD, R. How to study and market your device. FDA. 2024. https:\/\/www.fda.gov\/medical-devices\/device-advice-comprehensive-regulatory-assistance\/how-study-and-market-your-device."},{"key":"4351_CR29","unstructured":"Health, C. for D. and R. Premarket Approval (PMA). FDA. 2023. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/premarket-approval-pma."},{"key":"4351_CR30","unstructured":"FDA. Code of federal regulations title 21. 1980."},{"key":"4351_CR31","unstructured":"Waxman, Rep., Henry, A [D-CA-24]. (Introduced 08\/02\/1989). Safe Med Devices Act. 1990."},{"key":"4351_CR32","unstructured":"US FDA. Humanitarian device exemption (HDE) program - guidance for industry and Food and Drug Administration Staff. 2019."},{"key":"4351_CR33","unstructured":"Health CFD, R. Humanitarian device exemption. FDA. 2025. https:\/\/www.fda.gov\/medical-devices\/premarket-submissions-selecting-and-preparing-correct-submission\/humanitarian-device-exemption."},{"key":"4351_CR34","unstructured":"Health CFD, R. Getting a humanitarian use device to market. FDA. 2023. https:\/\/www.fda.gov\/medical-devices\/humanitarian-device-exemption\/getting-humanitarian-use-device-market."},{"key":"4351_CR35","unstructured":"Commissioner OOT. Pediatric device consortia grants program. FDA. 2023. https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/pediatric-device-consortia-grants-program."},{"key":"4351_CR36","unstructured":"Commissioner OOT. Orphan products grants program. FDA. 2023. https:\/\/www.fda.gov\/industry\/medical-products-rare-diseases-and-conditions\/orphan-products-grants-program."},{"key":"4351_CR37","unstructured":"Japan Minister of Health, Labour and Welfare. the article 77\u20132 of the Pharmaceutical affairs law."},{"key":"4351_CR38","unstructured":"Ministry of Health. Labour and Welfare: pharmaceuticals and medical devices. https:\/\/www.mhlw.go.jp\/english\/policy\/health-medical\/pharmaceuticals\/orphan_drug.html."},{"key":"4351_CR39","unstructured":"Research and resources. https:\/\/www.nibiohn.go.jp\/nibio\/english\/part\/."},{"key":"4351_CR40","unstructured":"Regulation (EU) 2017\/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, Amending Directive 2001\/83\/EC, Regulation (EC) No 178\/2002 and Regulation (EC) No 1223\/2009 and Repealing Council Directives 90\/385\/EEC and 93\/42\/EEC (Text with EEA Relevance.). OJ L. 2017;117."},{"key":"4351_CR41","unstructured":"Transitional provisions - European Commission. 2024. https:\/\/health.ec.europa.eu\/medical-devices-vitro-diagnostics\/transitional-provisions_en."},{"key":"4351_CR42","unstructured":"European Commission. Public consultation rare diseases: europe\u2019s challenges. 2007."},{"issue":"3","key":"4351_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.29245\/2572-9411\/2016\/3.1058","volume":"1","author":"M Dooms","year":"2016","unstructured":"Dooms M. Orphan devices for the surgical treatment of patients with rare diseases: present status and recommendations for the future. J Rare Dis Res Treat. 2016;1(3):71\u201373. https:\/\/doi.org\/10.29245\/2572-9411\/2016\/3.1058.","journal-title":"J Rare Dis Res Treat"},{"key":"4351_CR44","unstructured":"European Commission. European Health Union. Supporting the transition to the new medical device framework. 2023."},{"key":"4351_CR45","unstructured":"Medical Device Coordination Group. MDCG position paper: transition to the MDR and IVDR. (2022)."},{"key":"4351_CR46","unstructured":"Article 59 Archives. Medical device regulation. https:\/\/www.medical-device-regulation.eu\/tag\/article-59\/."},{"key":"4351_CR47","unstructured":"China National Medical Products Administration. Notice of the State Drug Administration on the public consultation on the \u2018measures for the administration of medical device registration (Revised Draft for Comment)\u2019. 2021. https:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/20210326094015179.html."},{"key":"4351_CR48","doi-asserted-by":"crossref","unstructured":"Wong A, Xu M. China accelerates medical device regulatory reform with new medical device regulations. 2021. https:\/\/www.twobirds.com\/en\/insights\/2021\/china\/china-accelerates-medical-device-regulatory-reform-with-new-medical-device-regulations.","DOI":"10.1201\/9781003207696-30"},{"issue":"3","key":"4351_CR49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/irdr.2021.01027","volume":"10","author":"Z Ying","year":"2021","unstructured":"Ying Z, Gong L, Li C. An update on China\u2019s national policies regarding rare diseases. IRDR. 2021;10(3):148\u201353. https:\/\/doi.org\/10.5582\/irdr.2021.01027.","journal-title":"IRDR"},{"key":"4351_CR50","unstructured":"Brazilian Health Regulatory Agency (Anvisa). - Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria - Anvisa. https:\/\/www.gov.br\/anvisa\/pt-br\/english."},{"key":"4351_CR51","unstructured":"RESOLU\u00c7\u00c3O - RDC. DE 25 DE FEVEREIRO DE, 2022 - RESOLU\u00c7\u00c3O - RDC No 608, DE 25 DE FEVEREIRO DE, 2022 - DOU - Imprensa Nacional. No 608. https:\/\/www.in.gov.br\/en\/web\/dou\/-\/resolucao-rdc-n-608-de-25-de-fevereiro-de-2022-383099033."},{"key":"4351_CR52","unstructured":"The innovative devices access pathway (IDAP). GOV.UK. 2024. https:\/\/www.gov.uk\/government\/publications\/the-innovative-devices-access-pathway-idap."},{"key":"4351_CR53","unstructured":"Health CFD, R. U.S.-Japan regulatory collaboration. FDA. 2023. https:\/\/www.fda.gov\/medical-devices\/cdrh-international-affairs\/us-japan-regulatory-collaboration."},{"key":"4351_CR54","unstructured":"HBD (Harmonization By Doing). | Pharmaceuticals and medical devices Agency. https:\/\/www.pmda.go.jp\/english\/int-activities\/int-harmony\/0028.html."},{"key":"4351_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.carrev.2023.02.015","volume":"52","author":"S Iwamoto","year":"2023","unstructured":"Iwamoto S, Cavanaugh K, Malone M, Lottes A, Thatcher R, Kumar K, et al. Global medical device clinical Trials involving both the United States and Japan: key Considerations for development, regulatory approval, and conduct. Cardiovasc Revascularization Med. 2023;52:67\u201374. https:\/\/doi.org\/10.1016\/j.carrev.2023.02.015.","journal-title":"Cardiovasc Revascularization Med"},{"issue":"5","key":"4351_CR56","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1253\/circj.CJ-19-1092","volume":"84","author":"S Takahashi","year":"2020","unstructured":"Takahashi S, Ibrahim N, Yasukochi S, Ringel R, Ing F, Tomita H, et al. Partnership between Japan and the United States for Early development of pediatric medical devices harmonization by doing for children. Circ J. 2020;84(5):786\u201391. https:\/\/doi.org\/10.1253\/circj.CJ-19-1092.","journal-title":"Circ J"},{"key":"4351_CR57","unstructured":"Medical Device Coordination Group Document. MDCG 2021\u20133 questions and answers on custom-made devices & considerations on adaptable medical devices and patient-matched medical devices. 2021. https:\/\/ec.europa.eu\/health\/system\/files\/2021-03\/mdcg_2021-3_en_0.pdf."},{"key":"4351_CR58","unstructured":"FDA. Custom device exemption - guidance for industry and Food and Drug Administration Staff. 2014."},{"key":"4351_CR59","unstructured":"States U. Pediatric medical device safety and Improvement Act (PMDSIA), Food and Drug Administration amendments Act of 2007. 2007."},{"key":"4351_CR60","unstructured":"Pediatric device innovators Forum - about. https:\/\/www.pdiforum.org\/about."},{"key":"4351_CR61","unstructured":"Funding & tenders. https:\/\/ec.europa.eu\/info\/funding-tenders\/opportunities\/portal\/screen\/opportunities\/topic-details\/eu4h-2023-pj-11."},{"key":"4351_CR62","unstructured":"i4KIDS. Europe paediatric innovation situation report i4KIDS-EUROPE. i4KIDS. https:\/\/www.innovation4kids.org\/en\/europe-paediatric-innovation-situation-report\/(2024)."},{"key":"4351_CR63","unstructured":"A. OrphaDev4Kids project approved. EPTRI. https:\/\/eptri.eu\/news\/orphadev4kids-project-approved\/(2024)."},{"key":"4351_CR64","unstructured":"D. Develop Child and orphan device evaluation support. https:\/\/decode-rd.com\/."},{"key":"4351_CR65","unstructured":"SHIP-MD | critical path Institute. https:\/\/c-path.org\/ship-md\/."},{"key":"4351_CR66","unstructured":"Pediatric medical devices design phase. FNIH. https:\/\/fnih.org\/our-programs\/pediatric-medical-devices-design-phase\/."},{"key":"4351_CR67","unstructured":"European expert recommendations on clinical investigation and evaluation of high-risk medical devices for children - guerlich - acta paediatrica -. Wiley Online Library. https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apa.16919."},{"key":"4351_CR68","unstructured":"Homepage. EPTRI. https:\/\/eptri.eu\/."},{"key":"4351_CR69","unstructured":"Pediatric Innovation Hub. i4KIDS. https:\/\/www.innovation4kids.org\/en\/."},{"key":"4351_CR70","unstructured":"Mayall B. The sociology of childhood and children\u2019s rights. In: Routledge International Handbook of Children\u2019s rights studies. Routledge; 2015."},{"issue":"12","key":"4351_CR71","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.3390\/pharmaceutics13122178","volume":"13","author":"P Dimitri","year":"2021","unstructured":"Dimitri P, Pignataro V, Lupo M, Bonifazi D, Henke M, Musazzi UM, et al. Medical device development for children and young people\u2014reviewing the challenges and opportunities. Pharmaceutics. 2021;13(12):2178. https:\/\/doi.org\/10.3390\/pharmaceutics13122178.","journal-title":"Pharmaceutics"},{"key":"4351_CR72","unstructured":"Health CFD, R. CDRH patient engagement. FDA. 2022. https:\/\/www.fda.gov\/about-fda\/division-patient-centered-development\/cdrh-patient-engagement."},{"key":"4351_CR73","unstructured":"Health CFD, R. Division of patient-centered development. FDA. 2024. https:\/\/www.fda.gov\/about-fda\/center-devices-and-radiological-health\/division-patient-centered-development."},{"issue":"6","key":"4351_CR74","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.nmd.2016.04.005","volume":"26","author":"A Bergsma","year":"2016","unstructured":"Bergsma A, Lobo-Prat J, Vroom E, Furlong P, Herder JL, Bergsma A, et al. 1st Workshop on upper-extremity assistive technology for people with Duchenne: state of the art, emerging avenues, and challenges. Neuromuscul Disord. 2016, 1st;26(6):386\u201393. https:\/\/doi.org\/10.1016\/j.nmd.2016.04.005.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"4351_CR75","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.nmd.2019.07.005","volume":"29","author":"MMHP Janssen","year":"2019","unstructured":"Janssen MMHP, Lobo-Prat J, Bergsma A, Vroom E, Bergsma A, Reinkensmeyer D, et al. 2nd Workshop on upper-extremity assistive technology for people with Duchenne: effectiveness and usability of arm supports Irvine, Usa, 22nd\u201323rd January 2018. Neuromuscul Disord. 2019;29(8):651\u201356. https:\/\/doi.org\/10.1016\/j.nmd.2019.07.005.","journal-title":"Neuromuscul Disord"},{"key":"4351_CR76","unstructured":"Nv E. epihunter. https:\/\/www.epihunter.com\/nl\/."},{"key":"4351_CR77","doi-asserted-by":"publisher","unstructured":"Japaridze G, Loeckx D, Buckinx T, Armand Larsen S, Proost R, Jansen K, et al. Automated detection of absence seizures using a wearable electroencephalographic device: a phase 3 validation study and feasibility of automated behavioral testing. Epilepsia. 2023;64(S4). https:\/\/doi.org\/10.1111\/epi.17200.","DOI":"10.1111\/epi.17200"},{"issue":"5","key":"4351_CR78","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/2168479017706405","volume":"51","author":"J Geissler","year":"2017","unstructured":"Geissler J, Ryll B, di Priolo SL, Uhlenhopp M. Improving patient involvement in medicines research and development: a practical roadmap. Ther Innov Regul Sci. 2017;51(5):612\u201319. https:\/\/doi.org\/10.1177\/2168479017706405.","journal-title":"Ther Innov Regul Sci"},{"key":"4351_CR79","unstructured":"Pharmaceuticals and Medical Devices Agency Patient Centricity Working Group. Pharmaceuticals and medical devices Agency guidance on patient participation. 2021."},{"key":"4351_CR80","unstructured":"Patient Centricity WG | Pharmaceuticals and medical devices Agency. https:\/\/www.pmda.go.jp\/english\/rs-sb-std\/rs\/0022.html."},{"issue":"42","key":"4351_CR81","doi-asserted-by":"publisher","first-page":"59608","DOI":"10.1007\/s11356-021-16345-5","volume":"28","author":"D Joshi","year":"2021","unstructured":"Joshi D, Sharma I, Gupta S, Singh TG, Dhiman S, Prashar A, et al. A global comparison of implementation and effectiveness of materiovigilance program: overview of regulations. Environ Sci Pollut Res Int. 2021;28(42):59608\u201329. https:\/\/doi.org\/10.1007\/s11356-021-16345-5.","journal-title":"Environ Sci Pollut Res Int"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04351-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04351-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:56:46Z","timestamp":1781737006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04351-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4351"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04351-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The views expressed in this article are the personal views of the author(s) and may not be understood as being made on behalf of their employ-er(s)\/organization(s).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"224"}}